Keros Therapeutics, Inc.

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

Keros Therapeutics expects a $20 million development milestone payment from partner Takeda after the first patient was dosed in the ELRiSE MF Phase 3 trial of elritercept in myelofibrosis. Keros will distribute 25% of the net cash proceeds to stockholders following receipt. Under the January 2025 license, Keros already received a $200 million upfront and is eligible for milestones potentially exceeding $1.1 billion plus tiered royalties. The trial tests elritercept versus placebo in myelofibrosis patients with anemia on concurrent ruxolitinib therapy, keeping the Takeda-partnered program on track.

•1mo ago

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics dosed the first patient in the Phase 2 clinical trial of rinvatercept in Duchenne muscular dystrophy (NCT07704099). The open-label, multi-cohort basket trial will assess safety and tolerability in late-ambulatory and early non-ambulatory DMD patients, with secondary objectives covering pharmacokinetics and functional improvements across muscle, motor, cardiac and pulmonary measures. Rinvatercept is Keros' lead asset, also in development for ALS; the milestone advances the neuromuscular strategy but clinical data remain the real catalyst.

•1mo ago

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

Keros Therapeutics' Board approved a $5 million share repurchase program following receipt of a $20 million milestone payment from Takeda. Management may repurchase shares in the open market or through other means, subject to market conditions and contractual limitations. The program does not obligate the company to repurchase any specific dollar amount or number of shares.

•1mo ago

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Keros Therapeutics announced the initiation of a Phase 2 clinical trial evaluating rinvatercept in patients with Duchenne muscular dystrophy, with initial data expected in the first half of 2027. The company reported a Q2 2026 net loss of $28.7 million, an improvement from the $30.7 million loss in the prior year, driven primarily by decreased R&D expenses following the transition of elritercept to Takeda. Cash and cash equivalents were $257.6 million as of June 30, 2026, which management expects will fund operations into the first half of 2028.

•2mo ago

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

Keros Therapeutics will receive a $20 million milestone payment from partner Takeda following the dosing of the first patient in the Phase 3 ELRiSE MDS trial of elritercept. The payment is part of a global license agreement that includes $200 million already received upfront and potential total milestones exceeding $1.1 billion. The company plans to distribute 25% of the net proceeds from this payment to stockholders.

•3mo ago

Keros Therapeutics Appoints Anne Prener to its Board of Directors

Keros Therapeutics appointed Anne Prener, M.D., Ph.D., to its Board of Directors effective July 1, 2026, adding significant clinical development and executive leadership experience to the board. Dr. Prener previously served as CEO of Imbria Pharmaceuticals, Freeline Therapeutics, and Gyroscope Therapeutics, and held senior leadership roles at Novo Nordisk and Baxalta. The company continues to advance its pipeline of protein therapeutics targeting the TGF-ß family, including lead candidates rinvatercept and elritercept.

•4mo ago